Ozonetherapy as a possible biological response modifier in cancer

Forschende Komplementarmedizin und Klassische Naturheilkunde

Volumn 5, Issue 2, 1998, Pages 54-60

  Bocci, V ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Autohaemotherapy; Cytokines; Leucocytes; Neoplasia; Ozone; Psychoneuroimmunology

Indexed keywords

EID: 0004633592     PISSN: 14247364     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Bailar JC III, Gornik HL: Cancer undefeated. N Engl J Med 1997;336:1569-1574.
2. Kramer BS, Klausner RD: Grappling with cancer, defeatism versus the reality of progress. N Engl J Med 1997; 337:931-934.
3. Bocci V: Immunomodulators as local hormones: New insights regarding their clinical utilization. J Biol Respir Modif 1985; 4:340-352.
4. Bocci V: Metabolism of protein anticancer agents. (Updated and reprinted in 1994 in Int. Encyclopedia of Pharmacology and Therapeutics, Sec. 140 Anticancer Drugs, Oxford, Pergamon Press, pp 387-436). Pharmacol Ther 1987;34:1-49.
5. Bocci V: Tumor therapy with biological response modifiers. Why is progress slow? EOS J Immunol Immunopharmacol 1990;10:79-82.
6. Kim CJ, Taubenberger JK, Simonis TB, White DE, Rosenberg SA, Marincola FM: Combination therapy with interferon-γ and interleukin-2 for the treatment of metastatic melanoma. J Immunother 1996;19:50-58.
7. Fenton RG, Steis RG, Madara K, Zea AH, Ochoa AC, Janik JE, Smith JW II, Gause BL, Sharfman WH, Urba WJ, Hanna MG, DeJager RL, Coyne MX, Crouch RD; Gray P, Beveridge J, Creekmore SP, Holmlund J, Curti BD, Sznol M, Longo DL: A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma. J Immunother 1996;19:364-374.
8. Werner GH, Jollès P: Immunostimulating agents: What next? A review of their present and potential medical applications. Eur J Biochem 1996;242:1-19.
9. Reddy SP, Harwood RM, Moore DF, Grimm EA, Murray JL, Vadhan-Raj S: Recombinant interleukin-2 in combination with recombinant interferon-γ in patients with advanced malignancy: A phase 1 study. J Immunother 1997;20:79-87.
10. Ernst E: Thymus therapy for cancer? A criteria-based, systematic review. Eur J Cancer 1997;33:531-535.
11. Bocci V: Immunologische Aspekte - eine kritische Betrachtung aus italienischer Sicht; in Beck, EG, Viebahn-Hänsler R (Hrsg): Ozon-Handbuch. Grundlagen. Prävention. Therapie. Landsberg, Ecomed, 1996, VII-2.3, p 1-16.
12. Bocci V: Ozone: A mixed blessing. New mechanisms of the action of ozone on blood cells make ozonated major autohaemotherapy (MAH) a rational approach. Forsch Komplementärmed 1996;3:25-33.
13. Bocci V: Ozone as a bioregulator. Pharmacology and toxicology of ozonetherapy today. J Biol Regul Homeost Agents 1996;10:31-53.
14. Bocci V, Luzzi E, Corradeschi F, Paulesu L, Di Stefano A: Studies on the biological effects of ozone: 3. An attempt to define conditions for optimal induction of cytokines. Lymphokine Cytokine Res 1993;12:121-126.
15. Bocci V, Luzzi E, Corradeschi F, Paulesu L: Studies on the biological effects of ozone: 5. Evaluation of immunological parameters and tolerability in normal volunteers receiving ambulatory autohaemotherapy. Biotherapy 1994;7:83-90.
16. Bocci V, Luzzi E, Corradeschi F, Silvestri S: Studies on the biological effects of ozone: 6. Production of transforming growth factor β1 by human blood after ozone treatment. J Biol Regul Homeost Agents 1994;8:108-112.
17. Beyerle: cited by G. Null in Ozone: A wide-spectrum healer. Penthouse Magazine, January 1996.
18. Baltin H: Ozonetherapy in oncology (abstract). Proceedings of the 12th Ozone World Congress, Lille, May 1995, p 41.
19. Ernst E, Resch KL: Evaluating specific effectiveness of complementary therapies - a position paper. Forsch Komplementärmed 1996;3:35-38.
20. Riethmüller G, Schlimok G, Kufer P, Gruber R, Holz E, Pantel K: Minimal residual disease in solid cancer: The diagnostic and therapeutic opportunity for monoclonal antibodies (abstract). 9th NCI-EORTC symposium on new drugs in cancer therapy, Amsterdam, March 12-15, 1996. Ann Oncol 1996;7(suppl 1):17.
21. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
22. Sweet F, Kao M-S, Lee S-CD, Hagar WL, Sweet WE: Ozone selectively inhibits growth of human cancer cells. Science 1980;209:931-933.
23. Szatrowski TP, Nathan CF: Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991;51:794-798.
24. Zänker KS, Kroczek R: The mistery of a molecule - ozone: Antiproliferative, immunomodulative, synergistic to chemotherapy and carcinogenic. Ozone in Medicine (vol 3). International Ozone Association; Proceedings of the Ninth Ozone World Congress, New York, USA, June 3-9, 1989, pp 55-68.
25. Shpall E, Jones R: Release of tumour cells from bone marrow. Blood 1994;83:623-626.
26. Hernàndez F, Menéndez S, Wong R: Decrease of blood cholesterol and stimulation of antioxidative response in cardiopathy patients treated with endovenous ozone therapy. Free Radic Biol Med 1995;19:115-119.
27. Viebahn-Hänsler R: Einfluss auf den Erythrozytenstoffwechsel; in Beck EG, Viebahn-Hänsler R (Hrsg): Ozon-Handbuch. Grundlagen - Prävention - Therapie. Landsberg, Ecomed, 1996, VII-2.1, pp 1-15.
28. Sporn MB, Roberts AB: A major advance in the use of growth factors to enhance wound healing. J Clin Invest 1993;92:2565-2566.
29. Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR, Park JB, Lazarev A, Graumlich JF, King J, Cantilena LR: Vitamin C pharmacokinetics in health volunteers: Evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 1996;93:3704-3709.
30. Reiter RJ, Oh C-S, Fujimori O: Melatonin. Its intracellular and genomic actions. Trends Endocrinol Metab 1996;7:22-27.
31. Bocci V: Does ozone therapy normalize the cellular redox balance? Med Hypotheses 1996;46:150-154.
32. Toyokuni S, Okamoto K, Yodoi J, Hiai H: Persistent oxidative stress in cancer. FEBS Lett 1995;358:1-3.
33. Dianzani F, Monahan T, Santiano M: Mechanism of induction of gamma interferon. Tex Rep Biol Med 1981;41:99-107.
34. Los M, Droge W, Stricker K, Baeuerle PA, Schulze-Osthoff K: Hydrogen peroxide as a potent activator of T lymphocyte functions. Eur J Immunol 1995;25:159-165.
35. Sen CK, Packer L: Antioxidant and redox regulation of gene transcription. FASEB J 1996;10:709-720.
36. Schreck R, Rieber P, Baeuerle PA: Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-KB transcription factor and HIV-1. EMBO J 1991;10:2247-2258.
37. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-897.
38. Kim S, Haas GP, Hillman GG: Development of immunotherapy for the treatment of malignancies refractory to conventional therapies. Cytokine Mol Ther 1996;2:13-19.
39. Reichlin S: Neuroendocrine-immune interactions. N Engl J Med 1993;329:1246-1253.
40. Blalock JE: The syntax of immune-neuroendocrine communication. Immunol Today 1994;15:504-511.
41. Flach J, Seachrist L: Mind-body meld may boost immunity. J Natl Cancer Inst 1994;86:256-258.
42. Bocci V: Administration of interferon at night may increase its therapeutic index. Cancer Drug Delivery 1985;2:313-318.